FHD-286
Phase 1Small molecule
FHD-286 is one of 81 small molecule programs targeting Uveal Melanoma. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Astplayer
AAstex Pharmaceuticals, Inc.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lenograstim
SanofiPhase 3
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Phase 3
Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Daunorubicin or Idarubicin
NovartisPhase 3
Histamine Dihydrochloride
MMaxim Pharmaceuticals
Phase 3
Azacitadine
AbbViePhase 3
HMPL-306
HHutchmed
Phase 3
Capoten
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Advanced Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FHD-286. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- FFoghorn Therapeutics Inc.